C3539919||Transarterial chemoembolization
C2239176||hepatocellular carcinoma
C0032718||segmental portal vein
C3163918||tumour thrombus
C3539919||transarterial chemoembolization
C3539919||transarterial chemoembolization
C2239176||hepatocellular carcinoma
C2239176||hepatocellular carcinoma
C0205122||segmental
C0032718||subsegmental portal vein
C3163918||tumour thrombus
C3163918||subsegmental portal vein tumour thrombus
C0232741||hepatic function
C0574032||chemoinfusion
C3539919||transarterial chemoembolization
C3539919||transarterial chemoembolization
C0574032||CI
C3539919||transarterial chemoembolization
C2347612||Child-Pugh score
C2239176||hepatocellular carcinoma
C3163918||subsegmental portal vein tumour thrombus
C3539919||transarterial chemoembolization
C0574032||CI
C1519255||serious adverse events
C1519255||serious adverse events
C3539919||transarterial chemoembolization
C0574032||CI
C3539919||transarterial chemoembolization
C0004002||aspartate aminotransferase
C3899975||Barcelona Clinic Liver Cancer (BCLC) stage D
C1517058||extrahepatic
C3539919||transarterial chemoembolization
C0574032||CI
C1519255||SAE
C3899974||BCLC stages
C3539919||transarterial chemoembolization
C0574032||CI
C1519255||SAE
C3539919||transarterial chemoembolization
C0087111||treatment
C2239176||hepatocellular carcinoma
C3163918||subsegmental portal vein tumour thrombus
C0232741||hepatic function
C0574032||chemoinfusion
C3539919||transarterial chemoembolization
C2239176||hepatocellular carcinoma
C3163918||subsegmental portal vein tumour thrombus
C3899974||BCLC stages
C0086930||risk
C3539919||transarterial chemoembolization
C0574032||chemoinfusion